{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:07:58Z","timestamp":1772118478327,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2011\/06887-1"],"award-info":[{"award-number":["2011\/06887-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2012\/18175-9"],"award-info":[{"award-number":["2012\/18175-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008353","name":"Funda\u00e7\u00e3o de Apoio ao Ensino, Pesquisa e Assist\u00eancia do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejps.2017.05.034","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T17:00:28Z","timestamp":1495040428000},"page":"S116-S123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S","title":["Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects"],"prefix":"10.1016","volume":"109","author":[{"given":"Natalicia de Jesus","family":"Antunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven C.","family":"van Dijkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Lucia","family":"Lanchote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauro","family":"Wichert-Ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Barbosa","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veriano","family":"Alexandre Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo Massaiti","family":"Takayanagui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Tozatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G. Coen","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.05.034_bb0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0010","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/chir.22231","article-title":"Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS\/MS: application in a pharmacokinetic study","volume":"25","author":"Antunes","year":"2013","journal-title":"Chirality"},{"key":"10.1016\/j.ejps.2017.05.034_bb0015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/jpet.105.085514","article-title":"Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity","volume":"314","author":"Clinckers","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.05.034_bb0020","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/bjp.2008.366","article-title":"Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain","volume":"155","author":"Clinckers","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00609428","article-title":"First dose and steady-state pharmacokinetics of oxcarbazepine and its l O-hydroxy metabolite","volume":"37","author":"Dickinson","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0030","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.addr.2012.09.042","article-title":"Intestinal drug transporters: an overview","volume":"65","author":"Estudante","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2017.05.034_bb0035","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.109.030593","article-title":"Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine abstract","volume":"39","author":"Flesch","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.05.034_bb0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/bdd.716","article-title":"Binding of licarbazepine enantiomers to mouse and human plasma proteins","volume":"31","author":"Fortuna","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.05.034_bb0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1528-1167.2012.03409.x","article-title":"Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique","volume":"53","author":"Fortuna","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.05.034_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-015-1970-4","article-title":"Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers","volume":"72","author":"de Jesus Antunes","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clpt.2005.11.001","article-title":"The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates","volume":"79","author":"Lemma","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.05.034_bb0060","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1528-1167.2005.00265.x","article-title":"A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine","volume":"46","author":"Marchi","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.05.034_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.05.034_bb0070","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.05.034_bb0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics.","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jchromb.2007.10.025","article-title":"Development and validation of a LC\/MS\/MS method for simultaneous quantification of oxcarbazepine and its main metabolites in human serum","volume":"860","author":"Paglia","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejps.2017.05.034_bb0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/WNF.0b013e31824150a5","article-title":"Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy","volume":"35","author":"Park","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00315422","article-title":"Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia","volume":"39","author":"Patsalos","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/17425255.2014.872630","article-title":"Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs","volume":"10","author":"Piana","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2017.05.034_bb0100","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1523\/JNEUROSCI.22-14-05833.2002","article-title":"Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance","volume":"22","author":"Rizzi","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejps.2017.05.034_bb0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"Suppl. 5","key":"10.1016\/j.ejps.2017.05.034_bb0110","first-page":"419","article-title":"Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine","volume":"35","author":"Schmutz","year":"1994","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.ejps.2017.05.034_bb0115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498258609043567","article-title":"The metabolism of 14C-oxcarbazepine in man","volume":"16","author":"Sch\u00fctz","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2017.05.034_bb0120","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s11095-009-9924-0","article-title":"The role of transporters in the pharmacokinetics of orally administered drugs","volume":"26","author":"Shugarts","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.05.034_bb0125","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1111\/j.1528-1157.1999.tb00918.x","article-title":"Oxcarbazepine","volume":"40","author":"Tecoma","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.05.034_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2009.10.011","article-title":"Bone and calcium metabolism and antiepileptic drugs","volume":"112","author":"Verrotti","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejps.2017.05.034_bb0135","first-page":"547","article-title":"Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine","volume":"66","author":"Volosoc","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.ejps.2017.05.034_bb0140","first-page":"419","article-title":"Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects","volume":"738","author":"Volosoc","year":"2000","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.ejps.2017.05.034_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00023210-200115020-00005","article-title":"Oxcarbazepine: an update of its efficacy in the management of epilepsy","volume":"15","author":"Wellington","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejps.2017.05.034_bb0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11095-016-2065-3","article-title":"A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations","volume":"34","author":"Yamamoto","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.05.034_bb0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s13318-015-0266-5","article-title":"Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy","volume":"41","author":"Yu","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.05.034_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance","volume":"30","author":"Zhang","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2017.05.034_bb0165","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T07:07:47Z","timestamp":1712473667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717302610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":33,"alternative-id":["S0928098717302610"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.05.034","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}